Radically truncated MeCP2 rescues Rett syndrome-like neurological defects

Nature

Volumn 550, Issue 7676, 2017, Pages

  Tillotson, Rebekah ^a   Selfridge, Jim ^a   Koerner, Martha V ^a   Gadalla, Kamal K E ^b,c   Guy, Jacky ^a   De Sousa, Dina ^a   Hector, Ralph D ^b   Cobb, Stuart R ^b   Bird, Adrian ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c TANTA UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

5 METHYLCYTOSINE; ADENO ASSOCIATED VIRUS VECTOR; METHYL CPG BINDING PROTEIN 2; DNA; MECP2 PROTEIN, MOUSE;

AMINO ACID; BRAIN; CELLS AND CELL COMPONENTS; DNA; GENE; GENE EXPRESSION; GENETIC ANALYSIS; MUTATION; NERVOUS SYSTEM DISORDER; PROTEIN; RNA;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARBOXY TERMINAL SEQUENCE; COMPARATIVE STUDY; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GENETIC CONSERVATION; GENETIC TRANSCRIPTION; HELA CELL LINE; METHYL-CPG-BINDING DOMAIN; MISSENSE MUTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RETT SYNDROME; RNA-BINDING DOMAIN; SINGLE NUCLEOTIDE POLYMORPHISM; 3T3 CELL LINE; ANIMAL; BRAIN; CHEMISTRY; DEFICIENCY; GENE DELETION; GENE THERAPY; GENETIC COMPLEMENTATION; GENETIC TRANSDUCTION; GENETICS; HUMAN; MALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; PROCEDURES; PROTEIN STABILITY;

MUS;

3T3 CELLS; ANIMALS; BRAIN; DNA; GENETIC COMPLEMENTATION TEST; GENETIC THERAPY; HELA CELLS; HUMANS; MALE; METHYL-CPG-BINDING PROTEIN 2; MICE; MUTATION, MISSENSE; PHENOTYPE; PROTEIN DOMAINS; PROTEIN STABILITY; RETT SYNDROME; SEQUENCE DELETION; TRANSDUCTION, GENETIC;

EID: 85031922947     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature24058     Document Type: Article

References (37)

1. Amir, R. E. et al. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet. 23, 185-188 (1999).
2. Lewis, J. D. et al. Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA. Cell 69, 905-914 (1992).
3. Skene, P. J. et al. Neuronal MeCP2 is expressed at near histone-octamer levels and globally alters the chromatin state. Mol. Cell 37, 457-468 (2010).
4. Lyst, M. J. & Bird, A. Rett syndrome: a complex disorder with simple roots. Nat. Rev. Genet. 16, 261-275 (2015).
5. Lyst, M. J. et al. Rett syndrome mutations abolish the interaction of MeCP2 with the NCoR/SMRT co-repressor. Nat. Neurosci. 16, 898-902 (2013).
6. Chahrour, M. et al. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science 320, 1224-1229 (2008).
7. Jeffery, L. & Nakielny, S. Components of the DNA methylation system of chromatin control are RNA-binding proteins. J. Biol. Chem. 279, 49479-49487 (2004).
8. Nan, X. et al. Interaction between chromatin proteins MECP2 and ATRX is disrupted by mutations that cause inherited mental retardation. Proc. Natl Acad. Sci. USA 104, 2709-2714 (2007).
9. Agarwal, N. et al. MeCP2 interacts with HP1 and modulates its heterochromatin association during myogenic differentiation. Nucleic Acids Res. 35, 5402-5408 (2007).
10. Cheng, T.-L. et al. MeCP2 suppresses nuclear microRNA processing and dendritic growth by regulating the DGCR8/Drosha complex. Dev. Cell 28, 547-560 (2014).
11. Young, J. I. et al. Regulation of RNA splicing by the methylation-dependent transcriptional repressor methyl-CpG binding protein 2. Proc. Natl Acad. Sci. USA 102, 17551-17558 (2005).
12. Della Ragione, F., Vacca, M., Fioriniello, S., Pepe, G. & D'Esposito, M. MECP2, a multi-talented modulator of chromatin architecture. Brief. Funct. Genomics 15, 420-431 (2016).
13. Nan, X., Meehan, R. R. & Bird, A. Dissection of the methyl-CpG binding domain from the chromosomal protein MeCP2. Nucleic Acids Res. 21, 4886-4892 (1993).
14. Kriaucionis, S. & Bird, A. The major form of MeCP2 has a novel N-terminus generated by alternative splicing. Nucleic Acids Res. 32, 1818-1823 (2004).
15. Nan, X., Tate, P., Li, E. & Bird, A. DNA methylation specifies chromosomal localization of MeCP2. Mol. Cell. Biol. 16, 414-421 (1996).
16. Kudo, S. et al. Heterogeneity in residual function of MeCP2 carrying missense mutations in the methyl CpG binding domain. J. Med. Genet. 40, 487-493 (2003).
17. Kruusvee, V. et al. Structure of the MeCP2-TBLR1 complex reveals a molecular basis for Rett syndrome and related disorders. Proc. Natl Acad. Sci. USA 114, E3243-E3250 (2017).
18. Guy, J., Gan, J., Selfridge, J., Cobb, S. & Bird, A. Reversal of neurological defects in a mouse model of Rett syndrome. Science 315, 1143-1147 (2007).
19. Cheval, H. et al. Postnatal inactivation reveals enhanced requirement for MeCP2 at distinct age windows. Hum. Mol. Genet. 21, 3806-3814 (2012).
20. Brown, K. et al. The molecular basis of variable phenotypic severity among common missense mutations causing Rett syndrome. Hum. Mol. Genet. 25, 558-570 (2016).
21. Guy, J., Hendrich, B., Holmes, M., Martin, J. E. & Bird, A. A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat. Genet. 27, 322-326 (2001).
22. Goffin, D. et al. Rett syndrome mutation MeCP2 T158A disrupts DNA binding, protein stability and ERP responses. Nat. Neurosci. 15, 274-283 (2011).
23. Shahbazian, M. et al. Mice with truncated MeCP2 recapitulate many Rett syndrome features and display hyperacetylation of histone H3. Neuron 35, 243-254 (2002).
24. Samaco, R. C. et al. A partial loss of function allele of methyl-CpG-binding protein 2 predicts a human neurodevelopmental syndrome. Hum. Mol. Genet. 17, 1718-1727 (2008).
25. Gadalla, K. K. E. et al. Development of a novel AAV gene therapy cassette with improved safety features and efficacy in a mouse model of Rett syndrome. Mol. Ther. Methods Clin. Dev. 5, 180-190 (2017).
26. Lagger, S. et al. MeCP2 recognizes cytosine methylated tri-nucleotide and di-nucleotide sequences to tune transcription in the mammalian brain. PLoS Genet. 13, e1006793 (2017).
27. Kinde, B., Wu, D. Y., Greenberg, M. E. & Gabel, H. W. DNA methylation in the gene body influences MeCP2-mediated gene repression. Proc. Natl Acad. Sci. USA 113, 15114-15119 (2016).
28. Baker, S. A. et al. An AT-hook domain in MeCP2 determines the clinical course of Rett syndrome and related disorders. Cell 152, 984-996 (2013).
29. Zhou, Z. et al. Brain-specific phosphorylation of MeCP2 regulates activitydependent Bdnf transcription, dendritic growth, and spine maturation. Neuron 52, 255-269 (2006).
30. Li, H., Zhong, X., Chau, K. F., Williams, E. C. & Chang, Q. Loss of activity-induced phosphorylation of MeCP2 enhances synaptogenesis, LTP and spatial memory. Nat. Neurosci. 14, 1001-1008 (2011).
31. Cong, L. et al. Multiplex genome engineering using CRISPR/VCas systems. Science 339, 819-823 (2013).
32. Clément, N. & Grieger, J. C. Manufacturing of recombinant adeno-associated viral vectors for clinical trials. Mol. Ther. Methods Clin. Dev. 3, 16002 (2016).
33. Gadalla, K. K. E. et al. Improved survival and reduced phenotypic severity following AAV9/MECP2 gene transfer to neonatal and juvenile male Mecp2 knockout mice. Mol. Ther. 21, 18-30 (2013).
34. Tao, J. et al. Phosphorylation of MeCP2 at serine 80 regulates its chromatin association and neurological function. Proc. Natl Acad. Sci. USA 106, 4882-4887 (2009).
35. Ebert, D. H. et al. Activity-dependent phosphorylation of MeCP2 threonine 308 regulates interaction with NCoR. Nature 499, 341-345 (2013).
36. Ho, K. L. et al. MeCP2 binding to DNA depends upon hydration at methyl-CpG. Mol. Cell 29, 525-531 (2008).
37. Lyst, M. J., Connelly, J., Merusi, C. & Bird, A. Sequence-specific DNA binding by AT-hook motifs in MeCP2. FEBS Lett. 590, 2927-2933 (2016).